viewZelda Therapeutics Ltd

Zelda Therapeutics reflects on busy December half

The company’s cash at bank was $4.41 million at the end of the 2018 calendar year.

Proactive interview with Dr Richard Hopkins
Zelda plans to value add all the way from clinical trials to the market

Zelda Therapeutics Ltd (ASX:ZLD) has made significant progress in its strategy to grow its business in the December half of 2018.

The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.

READ: Zelda Therapeutics on track to report on multiple clinical trials

Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.

Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Zelda also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA’s EU-GMP grade manufacturing capabilities and accessing its German distribution network

READ: Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute

Proactive spoke to Zelda’s managing director Dr Richard Hopkins about their vertically integrated strategy in December 2018.

Quick facts: Zelda Therapeutics Ltd

Price: 0.067 AUD

Market: ASX
Market Cap: $50.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelda Therapeutics Ltd named herein, including the promotion by the Company of Zelda Therapeutics Ltd in any Content on the Site, the Company...



Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...

on 12/3/19

2 min read